{"id":51585,"date":"2022-12-05T21:02:08","date_gmt":"2022-12-05T20:02:08","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/a-new-study-in-the-proceedings-of-the-national-academy-of-sciences-pnas-demonstrates-the-ability-of-a-novel-peptide-to-selectively-detect-and-neutralize-an-early-molecular-trigger-of-alzheimer\/"},"modified":"2022-12-05T21:02:08","modified_gmt":"2022-12-05T20:02:08","slug":"a-new-study-in-the-proceedings-of-the-national-academy-of-sciences-pnas-demonstrates-the-ability-of-a-novel-peptide-to-selectively-detect-and-neutralize-an-early-molecular-trigger-of-alzheimer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/a-new-study-in-the-proceedings-of-the-national-academy-of-sciences-pnas-demonstrates-the-ability-of-a-novel-peptide-to-selectively-detect-and-neutralize-an-early-molecular-trigger-of-alzheimer\/","title":{"rendered":"A New Study in the Proceedings of the National Academy of Sciences (PNAS) Demonstrates the Ability of a Novel Peptide to Selectively Detect and Neutralize an Early Molecular Trigger of Alzheimer\u2019s and Other Neurodegenerative Diseases"},"content":{"rendered":"
\n

\nAltPep Corporation is developing a unique platform to target disease many years before symptoms<\/i>\n<\/p>\n

SEATTLE–(BUSINESS WIRE)–AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced that this week the Proceedings of the National Academy of Sciences (PNAS) will publish results of a groundbreaking study demonstrating a customized, synthetic peptide\u2019s ability to selectively detect Alzheimer\u2019s disease. The novel approach detailed in “SOBA: Development and Testing of a Soluble Oligomer Binding Assay for Detection of Amyloidogenic Toxic Oligomers” allows detection of Alzheimer\u2019s disease at all stages, including presymptomatic cases, as well as differentiation from different amyloid-related neurodegenerative diseases. The technology was developed in the Daggett lab at the University of Washington, and AltPep is a spinout developing a revolutionary platform based on this technology focusing on early detection and treatments, with the aim to change the course of amyloid diseases.\n<\/p>\n

<\/a><\/p>\n

\n\u201cEarly diagnosis and treatment for Alzheimer\u2019s disease and other amyloid diseases have been elusive,\u201d said Valerie Daggett, Ph.D., Founder and CEO of AltPep. \u201cWe are targeting an early molecular trigger of amyloid diseases, a goal once thought to be unattainable. Our novel peptide platform is designed to selectively bind toxic oligomers, which is like finding a needle in a haystack. AltPep\u2019s technology is different from other approaches because it rationally targets a specific nonstandard protein structure discovered in the Daggett lab, called alpha-sheet. These toxic oligomers form both early and throughout the disease process.\u201d\n<\/p>\n

\nAmyloid diseases are associated with protein misfolding and aggregation of different toxic soluble oligomer proteins. For Alzheimer\u2019s disease, the formation of toxic amyloid beta-peptide (A\u03b2) oligomers is an early molecular trigger before other downstream events, such as plaque deposition and abnormal tau phosphorylation, take place. The aim is to intervene early in the disease pathway, before irreparable damage occurs, estimated to begin 10-20 years before clinically evident disease. Current treatment options are deployed too late, after a patient has signs and symptoms of the disease. This study demonstrates the ability of custom-designed, alpha-sheet peptides to both neutralize and detect these toxic oligomers in cerebrospinal fluid (CSF) and blood.\n<\/p>\n

\n\u201cThis peer-reviewed publication highlights the unique and broad potential of AltPep\u2019s platform to target multiple amyloid diseases,\u201d said Chad Robins, Board Member of AltPep and Co-founder and CEO of Adaptive Biotechnologies. \u201cThis is a pivotal time for the company, with groundbreaking science and a fantastic team to execute on its important mission.\u201d\n<\/p>\n

\nStudy Results<\/b>\n<\/p>\n

\nIn the study, Alzheimer\u2019s disease detection was achieved by testing 379 human plasma samples from 310 patients. The SOBA\u2122 assay detected A\u03b2 toxic oligomers in patients on the Alzheimer\u2019s disease continuum and discriminated from other forms of dementia with 99% sensitivity and specificity. In addition, the assay identified 13 samples from cognitively normal controls with high toxic oligomer levels. In subsequent years, 12 of the 13 were confirmed to progress to mild cognitive impairment (follow-up was not available for 1 individual). These results suggest that the SOBA assay can detect early Alzheimer\u2019s disease molecular pathology prior to clinical symptoms.\n<\/p>\n

\nTo demonstrate the broader application of the technology, CSF samples from patients with Parkinson\u2019s disease and Lewy body dementia were evaluated using the SOBA assay adapted for detection of Parkinson\u2019s disease-associated toxic oligomers. Strong signals and good discrimination between Parkinson\u2019s and Alzheimer\u2019s disease patients were seen, confirming proof of concept of the platform\u2019s modular and broad approach.\n<\/p>\n

\nAbout AltPep\u2019s SOBA<\/b>\u2122 Diagnostics and SOBIN<\/b>\u2122 Therapeutics<\/b>\n<\/p>\n

\nSOBA diagnostics are highly sensitive, simple blood tests in development to aid in the diagnosis of amyloid diseases. SOBIN therapeutics are in development for use in concert with early detection to target and neutralize the toxic soluble oligomers associated with amyloid diseases.\n<\/p>\n

\nAltPep has received Breakthrough Designation from the FDA for its SOBA-AD diagnostic for Alzheimer\u2019s disease. The inclusion in the FDA Breakthrough Devices Program means that AltPep can expect prioritized review of the submission of the diagnostic test.\n<\/p>\n

\nAbout AltPep Corporation<\/b>\n<\/p>\n

\nAltPep is developing groundbreaking disease-modifying treatments and detection tools for amyloid diseases by targeting early molecular triggers: toxic soluble oligomers. Our customized, synthetic peptides are designed to bind selectively to toxic oligomers in order to both detect and neutralize them throughout disease progression. AltPep\u2019s emphasis is on early, pre-symptomatic detection and treatment. Our lead programs focus on Alzheimer\u2019s and Parkinson\u2019s diseases, with other amyloid diseases on the horizon. AltPep\u2019s goal is to change the course of these debilitating diseases that affect over a billion people around the globe.\n<\/p>\n

\nDecades of scientific research by the Daggett Research Group at the University of Washington provided the foundation for AltPep\u2019s innovative approach.\n<\/p>\n

\nFor more information, please visit www.altpep.com<\/a> or follow us on LinkedIn.\n<\/p>\n

\nReference for publication: https:\/\/doi.org\/10.1073\/pnas.2213157119<\/a> (link live upon publication)\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMEDIA CONTACTS:<\/b>
Nancie Steinberg
\n
Bioscribe
\n
(917) 439-2054
\n
nancie@bioscribe.com<\/a><\/p>\n

Susan Sharpe
\n
Bioscribe
\n
(919) 602-2330
\n
susan@bioscribe.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

AltPep Corporation is developing a unique platform to target disease many years before symptoms SEATTLE–(BUSINESS WIRE)–AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced that this week the Proceedings of the National Academy of Sciences (PNAS) will publish results of a groundbreaking study demonstrating a … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51585","6":"format-standard","7":"category-industry"},"yoast_head":"\nA New Study in the Proceedings of the National Academy of Sciences (PNAS) Demonstrates the Ability of a Novel Peptide to Selectively Detect and Neutralize an Early Molecular Trigger of Alzheimer\u2019s and Other Neurodegenerative Diseases - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/a-new-study-in-the-proceedings-of-the-national-academy-of-sciences-pnas-demonstrates-the-ability-of-a-novel-peptide-to-selectively-detect-and-neutralize-an-early-molecular-trigger-of-alzheimer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"A New Study in the Proceedings of the National Academy of Sciences (PNAS) Demonstrates the Ability of a Novel Peptide to Selectively Detect and Neutralize an Early Molecular Trigger of Alzheimer\u2019s and Other Neurodegenerative Diseases - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"AltPep Corporation is developing a unique platform to target disease many years before symptoms SEATTLE–(BUSINESS WIRE)–AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced that this week the Proceedings of the National Academy of Sciences (PNAS) will publish results of a groundbreaking study demonstrating a ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/a-new-study-in-the-proceedings-of-the-national-academy-of-sciences-pnas-demonstrates-the-ability-of-a-novel-peptide-to-selectively-detect-and-neutralize-an-early-molecular-trigger-of-alzheimer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-05T20:02:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221205005157\/en\/1650490\/21\/AltPep_grey_redline_M.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/a-new-study-in-the-proceedings-of-the-national-academy-of-sciences-pnas-demonstrates-the-ability-of-a-novel-peptide-to-selectively-detect-and-neutralize-an-early-molecular-trigger-of-alzheimer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/a-new-study-in-the-proceedings-of-the-national-academy-of-sciences-pnas-demonstrates-the-ability-of-a-novel-peptide-to-selectively-detect-and-neutralize-an-early-molecular-trigger-of-alzheimer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"A New Study in the Proceedings of the National Academy of Sciences (PNAS) Demonstrates the Ability of a Novel Peptide to Selectively Detect and Neutralize an Early Molecular Trigger of Alzheimer\u2019s and Other Neurodegenerative Diseases\",\"datePublished\":\"2022-12-05T20:02:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/a-new-study-in-the-proceedings-of-the-national-academy-of-sciences-pnas-demonstrates-the-ability-of-a-novel-peptide-to-selectively-detect-and-neutralize-an-early-molecular-trigger-of-alzheimer\\\/\"},\"wordCount\":852,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/a-new-study-in-the-proceedings-of-the-national-academy-of-sciences-pnas-demonstrates-the-ability-of-a-novel-peptide-to-selectively-detect-and-neutralize-an-early-molecular-trigger-of-alzheimer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221205005157\\\/en\\\/1650490\\\/21\\\/AltPep_grey_redline_M.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/a-new-study-in-the-proceedings-of-the-national-academy-of-sciences-pnas-demonstrates-the-ability-of-a-novel-peptide-to-selectively-detect-and-neutralize-an-early-molecular-trigger-of-alzheimer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/a-new-study-in-the-proceedings-of-the-national-academy-of-sciences-pnas-demonstrates-the-ability-of-a-novel-peptide-to-selectively-detect-and-neutralize-an-early-molecular-trigger-of-alzheimer\\\/\",\"name\":\"A New Study in the Proceedings of the National Academy of Sciences (PNAS) Demonstrates the Ability of a Novel Peptide to Selectively Detect and Neutralize an Early Molecular Trigger of Alzheimer\u2019s and Other Neurodegenerative Diseases - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/a-new-study-in-the-proceedings-of-the-national-academy-of-sciences-pnas-demonstrates-the-ability-of-a-novel-peptide-to-selectively-detect-and-neutralize-an-early-molecular-trigger-of-alzheimer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/a-new-study-in-the-proceedings-of-the-national-academy-of-sciences-pnas-demonstrates-the-ability-of-a-novel-peptide-to-selectively-detect-and-neutralize-an-early-molecular-trigger-of-alzheimer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221205005157\\\/en\\\/1650490\\\/21\\\/AltPep_grey_redline_M.jpg\",\"datePublished\":\"2022-12-05T20:02:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/a-new-study-in-the-proceedings-of-the-national-academy-of-sciences-pnas-demonstrates-the-ability-of-a-novel-peptide-to-selectively-detect-and-neutralize-an-early-molecular-trigger-of-alzheimer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/a-new-study-in-the-proceedings-of-the-national-academy-of-sciences-pnas-demonstrates-the-ability-of-a-novel-peptide-to-selectively-detect-and-neutralize-an-early-molecular-trigger-of-alzheimer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/a-new-study-in-the-proceedings-of-the-national-academy-of-sciences-pnas-demonstrates-the-ability-of-a-novel-peptide-to-selectively-detect-and-neutralize-an-early-molecular-trigger-of-alzheimer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221205005157\\\/en\\\/1650490\\\/21\\\/AltPep_grey_redline_M.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221205005157\\\/en\\\/1650490\\\/21\\\/AltPep_grey_redline_M.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/a-new-study-in-the-proceedings-of-the-national-academy-of-sciences-pnas-demonstrates-the-ability-of-a-novel-peptide-to-selectively-detect-and-neutralize-an-early-molecular-trigger-of-alzheimer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"A New Study in the Proceedings of the National Academy of Sciences (PNAS) Demonstrates the Ability of a Novel Peptide to Selectively Detect and Neutralize an Early Molecular Trigger of Alzheimer\u2019s and Other Neurodegenerative Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"A New Study in the Proceedings of the National Academy of Sciences (PNAS) Demonstrates the Ability of a Novel Peptide to Selectively Detect and Neutralize an Early Molecular Trigger of Alzheimer\u2019s and Other Neurodegenerative Diseases - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/a-new-study-in-the-proceedings-of-the-national-academy-of-sciences-pnas-demonstrates-the-ability-of-a-novel-peptide-to-selectively-detect-and-neutralize-an-early-molecular-trigger-of-alzheimer\/","og_locale":"en_US","og_type":"article","og_title":"A New Study in the Proceedings of the National Academy of Sciences (PNAS) Demonstrates the Ability of a Novel Peptide to Selectively Detect and Neutralize an Early Molecular Trigger of Alzheimer\u2019s and Other Neurodegenerative Diseases - Pharma Trend","og_description":"AltPep Corporation is developing a unique platform to target disease many years before symptoms SEATTLE–(BUSINESS WIRE)–AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced that this week the Proceedings of the National Academy of Sciences (PNAS) will publish results of a groundbreaking study demonstrating a ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/a-new-study-in-the-proceedings-of-the-national-academy-of-sciences-pnas-demonstrates-the-ability-of-a-novel-peptide-to-selectively-detect-and-neutralize-an-early-molecular-trigger-of-alzheimer\/","og_site_name":"Pharma Trend","article_published_time":"2022-12-05T20:02:08+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221205005157\/en\/1650490\/21\/AltPep_grey_redline_M.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/a-new-study-in-the-proceedings-of-the-national-academy-of-sciences-pnas-demonstrates-the-ability-of-a-novel-peptide-to-selectively-detect-and-neutralize-an-early-molecular-trigger-of-alzheimer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/a-new-study-in-the-proceedings-of-the-national-academy-of-sciences-pnas-demonstrates-the-ability-of-a-novel-peptide-to-selectively-detect-and-neutralize-an-early-molecular-trigger-of-alzheimer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"A New Study in the Proceedings of the National Academy of Sciences (PNAS) Demonstrates the Ability of a Novel Peptide to Selectively Detect and Neutralize an Early Molecular Trigger of Alzheimer\u2019s and Other Neurodegenerative Diseases","datePublished":"2022-12-05T20:02:08+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/a-new-study-in-the-proceedings-of-the-national-academy-of-sciences-pnas-demonstrates-the-ability-of-a-novel-peptide-to-selectively-detect-and-neutralize-an-early-molecular-trigger-of-alzheimer\/"},"wordCount":852,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/a-new-study-in-the-proceedings-of-the-national-academy-of-sciences-pnas-demonstrates-the-ability-of-a-novel-peptide-to-selectively-detect-and-neutralize-an-early-molecular-trigger-of-alzheimer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221205005157\/en\/1650490\/21\/AltPep_grey_redline_M.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/a-new-study-in-the-proceedings-of-the-national-academy-of-sciences-pnas-demonstrates-the-ability-of-a-novel-peptide-to-selectively-detect-and-neutralize-an-early-molecular-trigger-of-alzheimer\/","url":"https:\/\/pharma-trend.com\/en\/a-new-study-in-the-proceedings-of-the-national-academy-of-sciences-pnas-demonstrates-the-ability-of-a-novel-peptide-to-selectively-detect-and-neutralize-an-early-molecular-trigger-of-alzheimer\/","name":"A New Study in the Proceedings of the National Academy of Sciences (PNAS) Demonstrates the Ability of a Novel Peptide to Selectively Detect and Neutralize an Early Molecular Trigger of Alzheimer\u2019s and Other Neurodegenerative Diseases - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/a-new-study-in-the-proceedings-of-the-national-academy-of-sciences-pnas-demonstrates-the-ability-of-a-novel-peptide-to-selectively-detect-and-neutralize-an-early-molecular-trigger-of-alzheimer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/a-new-study-in-the-proceedings-of-the-national-academy-of-sciences-pnas-demonstrates-the-ability-of-a-novel-peptide-to-selectively-detect-and-neutralize-an-early-molecular-trigger-of-alzheimer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221205005157\/en\/1650490\/21\/AltPep_grey_redline_M.jpg","datePublished":"2022-12-05T20:02:08+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/a-new-study-in-the-proceedings-of-the-national-academy-of-sciences-pnas-demonstrates-the-ability-of-a-novel-peptide-to-selectively-detect-and-neutralize-an-early-molecular-trigger-of-alzheimer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/a-new-study-in-the-proceedings-of-the-national-academy-of-sciences-pnas-demonstrates-the-ability-of-a-novel-peptide-to-selectively-detect-and-neutralize-an-early-molecular-trigger-of-alzheimer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/a-new-study-in-the-proceedings-of-the-national-academy-of-sciences-pnas-demonstrates-the-ability-of-a-novel-peptide-to-selectively-detect-and-neutralize-an-early-molecular-trigger-of-alzheimer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221205005157\/en\/1650490\/21\/AltPep_grey_redline_M.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221205005157\/en\/1650490\/21\/AltPep_grey_redline_M.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/a-new-study-in-the-proceedings-of-the-national-academy-of-sciences-pnas-demonstrates-the-ability-of-a-novel-peptide-to-selectively-detect-and-neutralize-an-early-molecular-trigger-of-alzheimer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"A New Study in the Proceedings of the National Academy of Sciences (PNAS) Demonstrates the Ability of a Novel Peptide to Selectively Detect and Neutralize an Early Molecular Trigger of Alzheimer\u2019s and Other Neurodegenerative Diseases"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51585","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51585"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51585\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51585"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51585"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51585"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}